Immunology / Virology & Vaccines

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Molecular medicine #Patent Law #Pharmacology #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics

Building a Robust Portfolio of New Medicines to Combat Malaria

Building a Robust Portfolio of New Medicines to Combat Malaria By Dr Timothy N.C. Wells Malaria is one of the biggest killers of our time. Current estimates from the World Health Organisation (WHO) suggest that more than 250 million people are at risk worldwide. More significantly, almost a million people… Read More

#Archive

#Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #RNA #Screening #System biology #Systems biology

Compound Storage Evolution: Unlocking the right combination

Compound Storage Evolution: Unlocking the right combination By Husam Fayez, Dr John Morin and Dr Jeff Paslay Delivering the correct compound, at the right concentration, to the correct place, at the expected time across different facilities, should be the aim of all liquid sample management teams. This article discusses how… Read More

#Archive

#Biomarkers #Business #Cell / tissue culture #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Preclinical #Regulatory #Target validation

Novartis Vaccines – Leading through innovation and technology

Novartis Vaccines - Leading through innovation and technology By Dr Joerg Reinhardt Every year, vaccines save millions of lives by preventing major human diseases, protecting individuals and those close to them, and offering widespread public defence against disease. In 2006, Novartis joined the vaccines market when it acquired Chiron, creating… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #Sequencing #Stem cells #System biology #Systems biology

21st Century Vaccines – A Development Renaissance

21st Century Vaccines - A Development Renaissance By Dr Jeff Stoddard, Charles Drucker and Dr Nigel Brown Human beings have benefited from vaccines for more than two centuries. From eradicating some of the deadliest diseases to nearly eliminating a host of others, including polio, measles, mumps and tetanus - vaccines… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Stem cells #Target validation

How Non-invasive Visible Light Imaging Can Change Drug Discovery

How Non-invasive Visible Light Imaging Can Change Drug Discovery Dr Peter Lassota and Dr Anjani Shah In the past decade, non-invasive visible light imaging gained acceptance not only as a valuable research tool, but also as a means of evaluating new compounds for efficacy and pharmacodynamic properties in drug discovery. Read More

#Archive

#Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Target validation #Therapeutics #Toxicology

Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens

Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models for testing… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Pharmacogenomics #Pharmacology #Regulatory #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The Biomedical Ecosystem Delivering Better Health and Prosperity

The Biomedical Ecosystem Delivering Better Health and Prosperity By Dr Peter B. Corr The overall message is simple: biomedical innovation and the public policies and new technologies that sustain and advance innovation are crucial to the future of biomedical science and the health and well being of our society. In… Read More

#Archive

#AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Immunology / Virology & Vaccines #Lead discovery #Oncology #Preclinical #RNA #Stem cells #Therapeutics

Immunomodulation: emerging from obscurity into a major therapeutic class

Immunomodulation: emerging from obscurity into a major therapeutic class By David Gee While not initially apparent, immunomodulation is high on the pharma agenda if recent deal making is a valid indicator. This article discusses the potential of immunomodulation to rise from the relative obscurity of adjuvants in vaccines to mainstream… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #Lead discovery #Pharmacology #Regulatory #RNA

How can we build sustainable European biopharmaceutical companies?

By Professor Simon Turton, Henry Makansi and Nick Lowcock Business models for emerging bioscience companies come in and out of fashion with some regularity, not always with obvious reason. This article examines what strategies have worked for the leading biopharmaceutical firms in Europe to try to identify what lessons there… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Immunology #Immunology / Virology & Vaccines #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA

Public Relations and the Drug Discovery Industry

Public Relations and the Drug Discovery Industry By Dr Richard Franklin The use of the Public Relations (PR) industry to promote all facets of the pharmaceutical industry is on the increase. We take a brief look at the various uses of PR and the sectors that are being promoted. Public… Read More

#Archive

#Academic #Analysis #Animal models #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Pharmokinetics #RNA #Stem cells #System biology #Systems biology

New developments in antigen-specific immunotherapies

New developments in antigen-specific immunotherapies By Dr Jorg Schneider and Professor Andrew J. McMichael Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Vaccination has been used effectively for more than 200 years to protect individuals from a range of infectious diseases such as polio… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Biosecurity #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Pathology #Precision medicine #Regulatory #RNA #System biology #Systems biology

Biotechnology, Bioterrorism & Biosecurity

Biotechnology, Bioterrorism & Biosecurity By Dr George Poste Advances in genetics and biotechnology offer great promise in the fight against infectious diseases. But the same technologies will also increase the threat from bioterrorism. Governments must accord 'biosecurity' a higher priority in defence and foreign policies to reduce the risk of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Cell culture #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #Therapeutics #Toxicology

Evaluating future drug candidates and their manufacture together

Evaluating future drug candidates and their manufacture together By Professor Peter Dunnill Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being… Read More

#Archive

#Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Toxicology

Surrogate Endpoints In Cancer Trials

Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Patent Law #Pharmacology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Protein Therapeutics – New ladders up the fruit tree

Protein Therapeutics - New ladders up the fruit tree By Dr Richard AG Smith Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or - in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics… Read More

#Archive